|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Cost of sales | |||||
| Gross profit | |||||
| Selling, general and administrative | |||||
| Research and development | |||||
| Acquired in-process research and development and milestones | |||||
| Goodwill impairment | |||||
| Restructuring costs | |||||
| Interest expense | |||||
| Exchange losses | |||||
| Other (income) expense, net | |||||
| Total, costs expenses and other | |||||
| Income before income taxes | |||||
| Income tax expense (benefit) | |||||
| Loss From Discontinued Operations - Net of Tax | |||||
| Net income | |||||
| Earnings per share: | |||||
| Discontinued operations (in dollars per share) | |||||
| Basic (in dollars per share) | |||||
| Continuing operations (in dollars per share) | |||||
| Discontinued operations (in dollars per share) | |||||
| Diluted (in dollars per share) | |||||
| Weighted average shares outstanding: | |||||
| Diluted (in shares) |
Loading...
